Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology

A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma†

(2013) A. C. Roy et al.   ANNALS OF ONCOLOGY

Phase I/II Trial of Nanomolecular Liposomal Annamycin in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

(2013) Meir Wetzler et al.   Clinical Lymphoma Myeloma & Leukemia

Strategies for triggered drug release from tumor targeted liposomes

(2013) Erik Oude Blenke et al.   Expert Opinion on Drug Delivery

Mild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacy

(2013) Li Li et al.   JOURNAL OF CONTROLLED RELEASE

Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia

(2013) Li Li et al.   JOURNAL OF CONTROLLED RELEASE

Impact of Tumor HER2/ERBB2 Expression Level on HER2-Targeted Liposomal Doxorubicin-Mediated Drug Delivery: Multiple Low-Affinity Interactions Lead to a Threshold Effect

(2013) B. S. Hendriks et al.   MOLECULAR CANCER THERAPEUTICS

Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors

(2012) Jeffrey R. Infante et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Meta-analysis of Nanoparticulate Paclitaxel Delivery System Pharmacokinetics and Model Prediction of Associated Neutropenia

(2012) Sihem Ait-Oudhia et al.   PHARMACEUTICAL RESEARCH

Physiologically Based Pharmacokinetic Model of Amphotericin B Disposition in Rats Following Administration of Deoxycholate Formulation (Fungizone®): Pooled Analysis of Published Data

(2011) Leonid Kagan et al.   AAPS Journal

Factors Controlling Nanoparticle Pharmacokinetics: An Integrated Analysis and Perspective

(2011) S.M. Moghimi et al.   Annual Review of Pharmacology and Toxicology

Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer

(2011) G. P. Stathopoulos et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Liposomal drug formulations in cancer therapy: 15 years along the road

(2011) Marije Slingerland et al.   DRUG DISCOVERY TODAY

Gemcitabine-loaded innovative nanocarriers vs GEMZAR: Biodistribution, pharmacokinetic features andin vivoantitumor activity

(2011) Christian Celia et al.   Expert Opinion on Drug Delivery

First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

(2011) Eric J. Feldman et al.   JOURNAL OF CLINICAL ONCOLOGY

Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study

(2010) Emilio Alba et al.   BREAST CANCER RESEARCH AND TREATMENT

Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma

(2010) Mary Cianfrocca et al.   CANCER

Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation

(2010) Maja J.A. de Jonge et al.   EUROPEAN JOURNAL OF CANCER

Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

(2010) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR®: Biodistribution, pharmacokinetic features and in vivo antitumor activity

(2010) Donatella Paolino et al.   JOURNAL OF CONTROLLED RELEASE

Delivering nanomedicine to solid tumors

(2010) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology

Novel PEG-coated niosomes based on bola-surfactant as drug carriers for 5-fluorouracil

(2009) D. Cosco et al.   BIOMEDICAL MICRODEVICES

Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma

(2009) M. A. Rodriguez et al.   CANCER

Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human breast cancer cell line MDA-MB 231

(2009) Sonia Aroui et al.   CANCER LETTERS

Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors

(2009) G. Batist et al.   CLINICAL CANCER RESEARCH

Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial

(2009) Maurie Markman et al.   GYNECOLOGIC ONCOLOGY

Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study

(2009) Joseph A. Sparano et al.   JOURNAL OF CLINICAL ONCOLOGY

Liposome drugs' loading efficiency: A working model based on loading conditions and drug's physicochemical properties

(2009) Daniel Zucker et al.   JOURNAL OF CONTROLLED RELEASE

Development of a highly stable and targetable nanoliposomal formulation of topotecan

(2009) Daryl C. Drummond et al.   JOURNAL OF CONTROLLED RELEASE

Paracrine sonic hedgehog signalling by prostate cancer cells induces osteoblast differentiation

(2009) Samantha M Zunich et al.   Molecular Cancer

Liposomal daunorubicinversusstandard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia

(2008) Roberto Latagliata et al.   BRITISH JOURNAL OF HAEMATOLOGY

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

(2008) Pieter Sonneveld et al.   CANCER

Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients

(2008) Jürgen B. Bulitta et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

(2008) M.-L. W. Ah-See et al.   CLINICAL CANCER RESEARCH

Development of Translational Pharmacokinetic–Pharmacodynamic Models

(2008) DE Mager et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Phase II Clinical Trial of Pegylated Liposomal Doxorubicin (JNS002) in Japanese Patients with Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having a Therapeutic History of Platinum-based Chemotherapy: A Phase II Study of the Japanese Gynecologic Oncology Group

(2008) N. Katsumata et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Influence of Drug-to-Lipid Ratio on Drug Release Properties and Liposome Integrity in Liposomal Doxorubicin Formulations

(2008) Michael J. W. Johnston et al.   JOURNAL OF LIPOSOME RESEARCH

Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development

(2008) Daryl C. Drummond et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Carboplatin and Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer: Preliminary Activity Results of the MITO-2 Phase III Trial

(2008) S. Pignata et al.   ONCOLOGY

Quantitative correlation between 1H MRS and dynamic contrast-enhanced MRI of human breast cancer

(2007) Hyeon-Man Baek et al.   MAGNETIC RESONANCE IMAGING